ESPE Yearbook of Paediatric Endocrinology

Pediatr Diabetes. 2021;1–7. doi: 10.1111/pedi.13191– The development of an awareness campaign and of a prospective registry in Mali enabled the collection of more accurate data on the incidence, prevalence and mortality of Type 1 diabetes (T1D) in children and youth <25 years– T1D incidence rose from 0.12 in 2007 to 0.74 in 2016 and T1D prevalence from 0.43 in 2007 to 2.90 in...

David.Beran@unige.ch Glob. Health Action 2022, VOL. 15, 2061239; doi: 10.1080/16549716.2022.2061239Brief Summary: In this perspective, the authors argue that non-governmental organisations (NGO), such as Santé Diabète, can play a role in the strengthening of health systems and can improve leadership and governance, service delivery and...

Pediatr Diabetes 2020;1–8. doi: 10.1111/pedi.13137– As part of the SWEET initiative, the authors analyzed the clinical characteristics of 26,726 individuals with type 1 diabetes (T1D) aged < 21 years living in Europe, Asia/Middle East/Africa, Australia/New Zealand, North America and South America– Among patient care indicators, the percent of HbA1c < 7.5% ranged between r...

prahalad@stanford.edu Pediatr Diabetes 2022; 23: 228–236. doi: 10.1111/pedi.13278Brief Summary: Analysis of the multi-national SWEET diabetes registry showed that mean HbA1c in youth is highest at diagnosis and lowest at 4 to 5 months post-diagnosis. The HbA1c trajectory was lower in countries with nationalized health insurance. High gross domestic p...

Brief Summary: This single-centre retrospective cohort study offers valuable insights into the trajectory of weight gain in a paediatric craniopharyngioma cohort over a mean follow-up period of 10.4 years, reinforcing the necessity for targeted interventions to address this issue.Craniopharyngioma poses a substantial clinical challenge in paediatric patients, primarily due to the risk of hypothalamic involvement. A particularly severe long-term consequen...

Brief Summary: This retrospective, observational, single centre study compared the risk of tumor progression or recurrence in 71 patients with childhood-onset craniopharyngioma (CP) who started GH replacement therapy (GHRT) with different latency from the end of tumor treatment.GHRT latency was defined as the time from end of CP treatment (last debulking procedure or radiotherapy, or from CP diagnosis for the 5 patients without any debulking procedure or...